sacubitril/valsartan (Entresto)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]

Indications

* improves cardiovascular & all-cause mortality vs enalopril[7]

* number needed to treat to prevent 1 cardiovascular death = 32

* improves physical & social activities[7]

* improves sexual function vs enalapril[7]

Contraindications

Dosage

Adverse effects

Drug interactions

Clinical trials

Notes

  • FDA-approved July 2015
  • direct to consumer advertising as Entresto on television

More general terms

Components

References

  1. ↑ 1.0 1.1 McMurray JJV et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014 Aug 30; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25176015 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1409077
  2. ↑ 2.0 2.1 2.2 FDA News Release. July 7, 2015 FDA approves new drug to treat heart failure http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm
  3. ↑ 3.0 3.1 Yancy CW et al Heart Failure Focused Update on Pharmacological Therapy. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation 2016 134: <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27208050 <Internet> http://circ.ahajournals.org/content/early/2016/05/18/CIR.0000000000000435.full.pdf+html
    J Am Coll Cardiol. 2016 May 17. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27216111 Free Article
    Antman EM et al Editorial: ACC/AHA/HFSA and ESC Updated Heart Failure Guideline Collaboration. Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. Circulation 2016 134: <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27216110 Free Article <Internet> http://circ.ahajournals.org/content/early/2016/05/18/CIR.0000000000000436.full.pdf+html
  4. ↑ 4.0 4.1 Desai AS et al Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. J Am Coll Cardiol. 2016;68(3):241-248 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27417000 Free Article <Internet> http://content.onlinejacc.org/article.aspx?articleid=2532918
    Mentz RJ, O'Brien EC Can 2 Pills a Day Keep Readmission Away? Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions. J Am Coll Cardiol. 2016;68(3):249-251 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27417001 <Internet> http://content.onlinejacc.org/article.aspx?articleid=2532923
  5. ↑ 5.0 5.1 Sandhu AT, Ollendorf DA, Chapman RH et al Cost-Effectiveness of Sacubitril - Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. Ann Intern Med. Published online 30 August 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27571284 <Internet> http://annals.org/article.aspx?articleid=2546543
  6. ↑ 6.0 6.1 Desai AS, Vardeny O, Claggett B et al Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/ Valsartan Compared With Enalapril. A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. Published online November 14, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27842179 <Internet> http://jamanetwork.com/journals/jamacardiology/article-abstract/2583456
    Ezekowitz JA Hyperkalemia, Sacubitril/Valsartan, and Mineralocorticoid Antagonists in Patients With Heart Failure. JAMA Cardiol. Published online November 14, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27842180 <Internet> http://jamanetwork.com/journals/jamacardiology/article-abstract/2583455
  7. ↑ 7.0 7.1 7.2 7.3 7.4 7.5 Chandra A, Lewis EF, Claggett BL et al Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart FailureA Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. Published online April 4, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29617523 https://jamanetwork.com/journals/jamacardiology/fullarticle/2677630
  8. ↑ 8.0 8.1 8.2 Velazquez EJ, Morrow DA, DeVore AD et al. PIONEER-HF Investigators Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2018 Nov 11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30415601 https://www.nejm.org/doi/10.1056/NEJMoa1812851
  9. ↑ 9.0 9.1 Solomon SD, McMurray JJV, Anand IS et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019 Sep 1; PMID: https://www.ncbi.nlm.nih.gov/pubmed/31475794 https://www.nejm.org/doi/10.1056/NEJMoa1908655
  10. ↑ Desai AS, Solomon SD, Shah AM et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: A randomized clinical trial. JAMA 2019 Sep 2; PMID: https://www.ncbi.nlm.nih.gov/pubmed/31475296 https://jamanetwork.com/journals/jama/article-abstract/2749477
    Januzzi JL Jr, Prescott MF, Butler J et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 2019 Sep 2 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31475295 https://jamanetwork.com/journals/jama/article-abstract/2749476
    Drazner MH. Angiotensin receptor-neprilysin inhibition (ARNI) therapy and reverse remodeling in heart failure with reduced ejection fraction. JAMA 2019 Sep 2; PMID: https://www.ncbi.nlm.nih.gov/pubmed/31475298 https://jamanetwork.com/journals/jama/article-abstract/2749474
  11. ↑ 11.0 11.1 McMurray JJV et al. Effects of sacubitril-valsartan, versus valsartan, in women compared to men with heart failure and preserved ejection fraction: Insights from PARAGON-HF. Circulation 2019 Nov 17; PMID: https://www.ncbi.nlm.nih.gov/pubmed/31736337 https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044491
  12. ↑ 12.0 12.1 12.2 Pieske B, Wachter R, Shah SJ et al Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction. The PARALLAX Randomized Clinical Trial. JAMA. 2021;326(19):1919-1929. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34783839 https://jamanetwork.com/journals/jama/fullarticle/2786245
    Redfield MM, Borlaug BA Quality of Life and Exercise Ability in Heart Failure With Preserved Ejection Fraction. No Time for Therapeutic Complacency. JAMA. 2021;326(19):1913-1915 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34783856 https://jamanetwork.com/journals/jama/fullarticle/2786265
  13. ↑ 13.0 13.1 Pfeffer MA, Claggett B, Lewis EF et al. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med 2021 Nov 11; 385:1845 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34758252 https://www.nejm.org/doi/10.1056/NEJMoa2104508
  14. ↑ 14.0 14.1 Mann DL, Givertz MM, Vader JM et al Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection FractionA Randomized Clinical Trial. JAMA Cardiol. 2022;7(1):17-25. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34730769 PMCID: PMC8567189 (available on 2022-11-03) https://jamanetwork.com/journals/jamacardiology/fullarticle/2785700
  15. ↑ 15.0 15.1 Medical Knowledge Self Assessment Program (MKSAP) 19 American College of Physicians, Philadelphia 2022
  16. ↑ 16.0 16.1 Vaduganathan M, Mentz RJ, Claggett BL et al Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J. 2023 Aug 14;44(31):2982-2993. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37210743 PMCID: PMC10424880 Free PMC article. Clinical Trial.
Retrieved from "https://aaushi.info/w/index.php?title=A445333&oldid=1166900"